Showing results (631-640 of 662) with videos related to

Sort By:
Pageof 67
Neuron|August 21, 2015
The Sorting Receptor SorCS1 Regulates Trafficking of Neurexin and AMPA ReceptorsJeffrey N Savas, Luís F Ribeiro, Keimpe D Wierda, et al.
Genome Medicine|May 9, 2022
Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune responseAnthony Z Wang, Jay A Bowman-Kirigin, Rupen Desai, et al.
Cancer Cell|March 19, 2020
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic CancerSamarth Hegde, Varintra E Krisnawan, Brett H Herzog, et al.
Cancer Discovery|September 27, 2022
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint BlockadeVarintra E Lander, Jad I Belle, Natalie L Kingston, et al.
Cancer Cell|May 26, 2023
Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunityXiuting Liu, Graham D Hogg, Chong Zuo, et al.
Plos One|August 21, 2014
Transcriptomic analysis of tail regeneration in the lizard Anolis carolinensis reveals activation of conserved vertebrate developmental and repair mechanismsElizabeth D Hutchins, Glenn J Markov, Walter L Eckalbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2024
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal AdenocarcinomaNaomi Yamamoto, Stephanie Dobersch, Ian Loveless, et al.
Science Translational Medicine|October 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapyXiuting Liu, John M Baer, Meredith L Stone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Pageof 67